📊 ZOMDF Key Takeaways
Is Zomedica Corp. (ZOMDF) a Good Investment?
Zomedica demonstrates strong unit economics (67.7% gross margin) and revenue growth, but faces an acute cash crisis with only $9M in liquidity against $17.6M annual operating burn, providing less than 6 months of runway. The company's path to profitability is opaque; operating losses of -$84.4M on $32M revenue suggest commercialization-phase R&D and sales expenses are unsustainable at the current burn rate without significant capital injection or dramatic operational restructuring.
Zomedica Corp. Key Strengths (ZOMDF)
- High gross margin of 67.7% indicates strong product economics and pricing power
- Revenue growth of 17.4% YoY demonstrates market traction and customer demand
- Pristine balance sheet with zero long-term debt and no financial obligations limiting flexibility
ZOMDF Stock Risks: Zomedica Corp. Investment Risks
- Critical liquidity crisis: $9M cash position vs. $17.6M annual operating burn rate implies less than 6 months until insolvency without funding
- Operating expenses are 263% of revenue; path to profitability is not evident and may require years of execution
- Negative free cash flow of -$18.2M annually; dilution risk is high if company pursues equity financing to survive
Key Metrics to Watch
- Cash burn rate and remaining cash runway—sustainability depends entirely on achieving positive cash flow or securing funding
- Operating expense trends relative to revenue growth—margin expansion is essential for viability
- Gross margin trajectory—any erosion would signal product pricing pressure or rising COGS, compounding distress
Zomedica Corp. (ZOMDF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.78x current ratio provides a solid financial cushion.
ZOMDF Profit Margin, ROE & Profitability Analysis
ZOMDF vs Healthcare Sector: How Zomedica Corp. Compares
How Zomedica Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zomedica Corp. Stock Overvalued? ZOMDF Valuation Analysis 2026
Based on fundamental analysis, Zomedica Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zomedica Corp. Balance Sheet: ZOMDF Debt, Cash & Liquidity
ZOMDF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zomedica Corp.'s revenue has grown significantly by 69% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.05 indicates the company is currently unprofitable.
ZOMDF Revenue Growth, EPS Growth & YoY Performance
ZOMDF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.5M | -$4.5M | $0.00 |
| Q3 2025 | $7.0M | -$6.1M | $-0.01 |
| Q2 2025 | $6.1M | -$7.4M | $-0.01 |
| Q1 2025 | $6.3M | -$9.2M | $-0.01 |
| Q3 2024 | $6.3M | -$491.0K | $0.00 |
| Q2 2024 | $6.0M | -$5.2M | $-0.01 |
| Q1 2024 | $5.5M | -$6.4M | $-0.01 |
| Q3 2023 | $4.8M | -$491.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zomedica Corp. Dividends, Buybacks & Capital Allocation
ZOMDF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zomedica Corp. (CIK: 0001684144)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZOMDF
What is the AI rating for ZOMDF?
Zomedica Corp. (ZOMDF) has an AI grade of D with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZOMDF's key strengths?
Claude: High gross margin of 67.7% indicates strong product economics and pricing power. Revenue growth of 17.4% YoY demonstrates market traction and customer demand.
What are the risks of investing in ZOMDF?
Claude: Critical liquidity crisis: $9M cash position vs. $17.6M annual operating burn rate implies less than 6 months until insolvency without funding. Operating expenses are 263% of revenue; path to profitability is not evident and may require years of execution.
What is ZOMDF's revenue and growth?
Zomedica Corp. reported revenue of $32.0M.
Does ZOMDF pay dividends?
Zomedica Corp. does not currently pay dividends.
Where can I find ZOMDF SEC filings?
Official SEC filings for Zomedica Corp. (CIK: 0001684144) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZOMDF's EPS?
Zomedica Corp. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZOMDF's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zomedica Corp. has a D grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZOMDF stock overvalued or undervalued?
Valuation metrics for ZOMDF: ROE of -70.9% (sector avg: 15%), net margin of -255.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZOMDF's AI grade for 2026?
Our dual AI analysis gives Zomedica Corp. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZOMDF's free cash flow?
Zomedica Corp.'s operating cash flow is $-17.6M, with capital expenditures of $567.0K. FCF margin is -56.9%.
How does ZOMDF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -255.6% (avg: 12%), ROE -70.9% (avg: 15%), current ratio 6.78 (avg: 2).